1. Abstract P1-13-11: Optimal omission of anthracycline in adjuvant chemotherapy of HER2 positive breast cancer
- Author
-
K Yuko, Rurina Watanuki, Tetsu Hayashida, Yuukou Kitagawa, Tomoko Seki, Ayako Nakashoji, Takamichi Yokoe, Maiko Takahashi, Tomoka Toyota, and Masayuki Kikuchi
- Subjects
Oncology ,Cancer Research ,Chemotherapy ,medicine.medical_specialty ,Cardiotoxicity ,Taxane ,Anthracycline ,business.industry ,medicine.medical_treatment ,Cancer ,medicine.disease ,chemistry.chemical_compound ,Breast cancer ,Paclitaxel ,chemistry ,Trastuzumab ,Internal medicine ,medicine ,skin and connective tissue diseases ,business ,medicine.drug - Abstract
[Background]In adjuvant settings of HER2 positive cancer, trastuzumab has been shown to be effective in combination with anthracycline- based chemotherapy followed by taxane-based chemotherapy. However, the role of anthracyclines for the treatment of breast cancer has remained in controversy,due to the increased risk of cardiotoxicity and secondary carcinogenesis. Recently, additional anthracycline-free treatment regimens have also been reported. In a single-arm multicenter trial of 406 patients treated with paclitaxel plus trastuzumab for Citation Format: Watanuki R, Hayashida T, Yuko K, Kikuchi M, Nakashoji A, Yokoe T, Toyota T, Seki T, Takahashi M, Kitagawa Y. Optimal omission of anthracycline in adjuvant chemotherapy of HER2 positive breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-13-11.
- Published
- 2019
- Full Text
- View/download PDF